RBC Capital Maintains Outperform on ResMed, Lowers Price Target to $273
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Craig Wong-Pan has maintained an 'Outperform' rating on ResMed (NYSE:RMD) but lowered the price target from $284 to $273.

August 14, 2023 | 11:56 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ResMed's price target has been lowered from $284 to $273 by RBC Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by RBC Capital could potentially create a negative sentiment among investors. However, the maintained 'Outperform' rating indicates that the analyst still sees potential in the stock, which could balance out the impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100